Immunotherapies for Alzheimer’s disease-Reference-Cited by-同舟云学术

Immunotherapies for Alzheimer’s disease

Published:2023-12-15 Issue:6676 Volume:382 Page:1242-1244
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Golde Todd E.¹,Levey Allan I.¹

Affiliation:

1. Department of Pharmacology and Chemical Biology, Department of Neurology, Center for Neurodegenerative Disease, Goizueta Institute Emory Brain Health, Emory University School of Medicine, Atlanta, GA, USA.

Abstract

Antibodies targeting amyloid-β aggregates slow decline in Alzheimer’s disease

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Link

https://www.science.org/doi/pdf/10.1126/science.adj9255

Reference15 articles.

1. S. Budd Haeberlein , J. Prev. Alzheimers Dis. 9, 197 (2022).

2. Donanemab in Early Symptomatic Alzheimer Disease

3. Lecanemab in Early Alzheimer’s Disease

4. Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

5. The informed road map to prevention of Alzheimer Disease: A call to arms

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies;Signal Transduction and Targeted Therapy;2024-08-23

2. Cancer research provides a model for advancing clinical trials in dementia in the era of disease-modifying Alzheimer’s-type dementia therapies;Alzheimer's Research & Therapy;2024-08-21

3. Novel Monoclonal Antibody Specific toward Amyloid-β Binds to a Unique Epitope within the N-Terminal Region;Antibodies;2024-08-09

4. Polyphenol-based polymer nanoparticles for inhibiting amyloid protein aggregation: recent advances and perspectives;Frontiers in Nutrition;2024-07-29

5. Exploring transfer effects on memory and its neural mechanisms through a computerized cognitive training in mild cognitive impairment: randomized controlled trial;Psychogeriatrics;2024-07-16